Topadur’s Phase 2a trial of TOP-N53 for systemic sclerosis-associated digital ulcers advances to next dose levels
Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced that the Safety Review Committee of its Phase 2a trial has recommended progression to the next planned dose levels.
Read original article on The Medical News →Related news
-
Review explores intrinsic mechanisms driving right ventricular remodeling in pulmonary arterial hypertension
United Kingdom
-
New covalent inhibitor targets DNAJC9 to reduce sepsis inflammation
United Kingdom
-
Innovative framework advances EEG-based emotion recognition
United Kingdom
-
Delivering integrated HIV and substance use services through mobile units could save lives
United Kingdom
-
Nail salon air monitoring reveals chemical spikes that traditional assessments may miss
United Kingdom
-
The Rest Deficit: Why I Can’t Stop Optimizing My Free Time
United Kingdom
-
HIV prevention medication is highly effective, but it can complicate blood donor screening
United Kingdom
-
Scientists discover mysterious “lonely” brain waves linked to memory loss
United States